Close
Close
Treatment Database
1-(fluoro-18F)-3-((2-((1E,3E)-4-(6-(methylamino)pyridin-3-yl)buta-1,3-dien-1-yl)benzo[d]thiazol-6-yl)oxy)propan-2-ol
Trade Name not avaiable
Orphan Indication A diagnostic for the management of progressive supranuclear palsy
USA Market Approval
USA Designation Date 01-11-2017
Sponsor Aprinoia Therapeutics
17F, No. 3 Yuanqu Street
Nangang District
More about Progressive supranuclear palsy
Free Newsletter
Related Videos